Breast & Ovarian Cancer
KnowBRCA: Hereditary Breast & Ovarian Cancer and Public Health - March 25, 2015
Diary of a surgery,
by Angelina Jolie Pitt, New York Times, Mar 24
by Angelina Jolie Pitt, New York Times, Mar 24What all patients can learn from Angelina Jolie, by Julia Belluz and Steven Hoffman, Vox, Mar 24
by Julia Belluz and Steven Hoffman, Vox, Mar 24'Jolie effect': Could her candor help save lives? By Maria Puente, USA Today, Mar 24
By Maria Puente, USA Today, Mar 24CDC Know:BRCA Tool
Some women carry certain genetic changes in their BRCA genes that increase their risks for getting breast, ovarian, and other kinds of cancers at a young age
Some women carry certain genetic changes in their BRCA genes that increase their risks for getting breast, ovarian, and other kinds of cancers at a young age
Knowing BRCA changed my life, by Debbie Wasserman Schultz, CDC Blog Post 2014
CDC information: Does breast or ovarian cancer run in your family?
Webinar: Hereditary breast and ovarian cancer in public health, Genetic Alliance, 2014
Genetic Alliance, 2014CDC Tier 1 Genomic Applications Implementation Toolkit for Public Health Departments
Detailed Information on Hereditary Breast and Ovarian Cancer (HBOC)
Detailed Information on Hereditary Breast and Ovarian Cancer (HBOC)
CDC Podcast: Genetics and BRCA in primary care, Medscape, 2014
Medscape, 2014Breast Cancer Gene Expression Profiling in Practice - March 13, 2015
Cost-effectiveness of the 21-gene breast cancer assay in Mexico.
Bargalló-Rocha JE et al. Adv Ther 2015 Mar 5.
Bargalló-Rocha JE et al. Adv Ther 2015 Mar 5.
Initial trends in the use of the 21-gene recurrence score assay for patients with breast cancer in the Medicare population, 2005-2009
Dinan MA, et al. JAMA Oncology, March 2015
Dinan MA, et al. JAMA Oncology, March 2015
The value of personalizing medicine: Medical oncologists? Views on gene expression profiling in breast cancer treatment
Bombard Y, et al. The Oncologist, March 2015
Bombard Y, et al. The Oncologist, March 2015
The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer.
Thaker NG, et al. Springerplus 2015 36
Thaker NG, et al. Springerplus 2015 36
Oncotype DX in women and men with ER-positive, HER2-negative early stage breast cancer who are lymph node negative: A review of clinical effectiveness and guidelines
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health 2014 Feb 20.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health 2014 Feb 20.
Clinical utility of gene-expression profiling in women with early breast cancer: an overview of systematic reviews.
Marrone M, et al. Genet. Med. 2014 Dec 4.
Marrone M, et al. Genet. Med. 2014 Dec 4.
[uPA/PAI-1, Oncotype DX, MammaPrint(®). Prognosis and predictive values for clinical utility in breast cancer management].
Bellocq JP, et al. Ann Pathol 2014 Oct (5) 349-51
Bellocq JP, et al. Ann Pathol 2014 Oct (5) 349-51
A study of the impact of the 21-gene breast cancer assay on the use of adjuvant chemotherapy in women with breast cancer in a Mexican public hospital.
Bargallo JE, et al. J Surg Oncol 2015 Feb (2) 203-7
Bargallo JE, et al. J Surg Oncol 2015 Feb (2) 203-7
Can mammographic and sonographic imaging features predict the Oncotype DX? recurrence score in T1 and T2, hormone receptor positive, HER2 negative and axillary lymph node negative breast cancers?
Yepes MM, et al. Breast Cancer Res. Treat. 2014 Nov (1) 117-23
Yepes MM, et al. Breast Cancer Res. Treat. 2014 Nov (1) 117-23
The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre.
McVeigh TP, et al. Eur. J. Cancer 2014 Nov (16) 2763-70
McVeigh TP, et al. Eur. J. Cancer 2014 Nov (16) 2763-70
Genomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspective.
Seguí MÁ et al. Expert Rev Pharmacoecon Outcomes Res 2014 Dec (6) 889-99
Seguí MÁ et al. Expert Rev Pharmacoecon Outcomes Res 2014 Dec (6) 889-99
Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor-positive, lymph-node-negative early-stage breast cancer in Japan.
Yamauchi H, et al. BMC Health Serv Res 2014 372
Yamauchi H, et al. BMC Health Serv Res 2014 372
Factors influencing Oncotype DX use in the management of early breast cancer: a single centre experience.
Zhu X, et al. Eur. J. Cancer 2014 Oct (15) 2544-9
Zhu X, et al. Eur. J. Cancer 2014 Oct (15) 2544-9
Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use.
Zanotti L, et al. Tumour Biol. 2014 Sep (9) 8461-70
Zanotti L, et al. Tumour Biol. 2014 Sep (9) 8461-70
Breast Cancer Genomics: Where Are We Going? - March 9, 2015
Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights.
Ng Charlotte K Y et al. J. Natl. Cancer Inst. 2015 (5)
Ng Charlotte K Y et al. J. Natl. Cancer Inst. 2015 (5)
Genomic profiling of breast cancers.
Curtis Christina et al. Curr. Opin. Obstet. Gynecol. 2015 Feb (1) 34-9
Curtis Christina et al. Curr. Opin. Obstet. Gynecol. 2015 Feb (1) 34-9
Intrinsic cancer subtypes-next steps into personalized medicine.
Santos Cristina et al. Cell Oncol (Dordr) 2015 Jan 14.
Santos Cristina et al. Cell Oncol (Dordr) 2015 Jan 14.
New concepts in breast cancer genomics and genetics.
Goncalves Rodrigo et al. Breast Cancer Res. 2014 (5) 460
Goncalves Rodrigo et al. Breast Cancer Res. 2014 (5) 460
Application of metabolomics in drug resistant breast cancer research.
Shajahan-Haq Ayesha N et al. Metabolites 2015 (1) 100-18
Shajahan-Haq Ayesha N et al. Metabolites 2015 (1) 100-18
Research progress in applying proteomics technology to explore early diagnosis biomarkers of breast cancer, lung cancer and ovarian cancer.
Luo Lu et al. Asian Pac. J. Cancer Prev. 2014 (20) 8529-38
Luo Lu et al. Asian Pac. J. Cancer Prev. 2014 (20) 8529-38
How many etiological subtypes of breast cancer: two, three, four, or more?
Anderson William F et al. J. Natl. Cancer Inst. 2014 Aug (8)
Anderson William F et al. J. Natl. Cancer Inst. 2014 Aug (8)
Computational prognostic indicators for breast cancer.
Yang Xinan et al. Cancer Manag Res 2014 301-12
Yang Xinan et al. Cancer Manag Res 2014 301-12
Genomic analysis of breast cancer heralds a changing treatment paradigm.
Ellis Matthew et al. J Natl Compr Canc Netw 2014 May (5 Suppl) 750-2
Ellis Matthew et al. J Natl Compr Canc Netw 2014 May (5 Suppl) 750-2
Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers.
Davis S Lindsey et al. Ther Adv Med Oncol 2014 May (3) 88-100
Davis S Lindsey et al. Ther Adv Med Oncol 2014 May (3) 88-100
Principles and methods of integrative genomic analyses in cancer.
Kristensen Vessela N et al. Nat. Rev. Cancer 2014 May (5) 299-313
Kristensen Vessela N et al. Nat. Rev. Cancer 2014 May (5) 299-313
Implications of functional proteomics in breast cancer.
Chae Young Kwang et al. Oncologist 2014 Apr (4) 328-35
Chae Young Kwang et al. Oncologist 2014 Apr (4) 328-35
Genetic and epigenetic aspects of breast cancer progression and therapy.
Byler Shannon et al. Anticancer Res. 2014 Mar (3) 1071-7
Byler Shannon et al. Anticancer Res. 2014 Mar (3) 1071-7
The omics of triple-negative breast cancers.
Xu Hong et al. Clin. Chem. 2014 Jan (1) 122-33
Xu Hong et al. Clin. Chem. 2014 Jan (1) 122-33
Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value.
Stirzaker Clare et al. Nat Commun 2015 5899
Stirzaker Clare et al. Nat Commun 2015 5899
Breast cancer genomics in the deep sequencing era.
Pillar Nir et al. Isr. Med. Assoc. J. 2014 Dec (12) 783-4
Pillar Nir et al. Isr. Med. Assoc. J. 2014 Dec (12) 783-4
Hereditary Breast and Ovarian Cancer: Is it time for Population Screening for BRCA Mutations? - February 17, 2015
A never-ending genetic quest. Mary-Claire King?s Pioneering gene work, from breast cancer to human rights, New York Times, Feb 9
, New York Times, Feb 9Precision medicine meets public health: population screening for BRCA1 and BRCA2.
Levy-Lahad Ephrat et al. J. Natl. Cancer Inst. 2015 Jan (1) 420
Levy-Lahad Ephrat et al. J. Natl. Cancer Inst. 2015 Jan (1) 420
Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.
Gabai-Kapara Efrat et al. Proc. Natl. Acad. Sci. U.S.A. 2014 Sep 30. (39) 14205-10
Gabai-Kapara Efrat et al. Proc. Natl. Acad. Sci. U.S.A. 2014 Sep 30. (39) 14205-10
Lasker Award winner Mary-Claire King.
King Mary-Claire et al. Nat. Med. 2014 Oct (10) 1124-5
King Mary-Claire et al. Nat. Med. 2014 Oct (10) 1124-5
Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award.
King Mary-Claire et al. JAMA 2014 Sep 17. (11) 1091-2
King Mary-Claire et al. JAMA 2014 Sep 17. (11) 1091-2
Cost-effectiveness of population screening for BRCA mutations in Ashkenazi Jewish women compared with family history-based testing.
Manchanda Ranjit et al. J. Natl. Cancer Inst. 2015 Jan (1) 380
Manchanda Ranjit et al. J. Natl. Cancer Inst. 2015 Jan (1) 380
Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial.
Manchanda Ranjit et al. J. Natl. Cancer Inst. 2015 Jan (1) 379
Manchanda Ranjit et al. J. Natl. Cancer Inst. 2015 Jan (1) 379
Ovarian Cancer: Recent Genomic Insights - January 20, 2015
Identification of six new susceptibility loci for invasive epithelial ovarian cancer
Karoline B Kuchenbaecker et al. Nature Genetics, January 12, 2015
Karoline B Kuchenbaecker et al. Nature Genetics, January 12, 2015
Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer.
Candido Dos Reis FJ, Clin Cancer Res. 2014 Nov 14
Candido Dos Reis FJ, Clin Cancer Res. 2014 Nov 14
Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An ovarian tumour tissue analysis consortium study.
Köbel M, et al. Br J Cancer. 2014 Dec 9;111(12):2297-307
Köbel M, et al. Br J Cancer. 2014 Dec 9;111(12):2297-307
New strategies in ovarian cancer: translating the molecular complexity of ovarian cancer into treatment advances.
Liu J, et al. Clin Cancer Res. 2014 Oct 15;20(20):5150-6
Liu J, et al. Clin Cancer Res. 2014 Oct 15;20(20):5150-6
Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
Emmanuel C, et al. Clin Cancer Res. 2014 Dec 15;20(24):6618-30.
Emmanuel C, et al. Clin Cancer Res. 2014 Dec 15;20(24):6618-30.
Knowledge-driven genomic interactions: an application in ovarian cancer.
Kim D, Li R, et al. BioData Min. 2014 Sep 9;7:20
Kim D, Li R, et al. BioData Min. 2014 Sep 9;7:20
Ovarian cancer biomarkers: current state and future implications from high-throughput technologies.
Leung F, et al. Adv Clin Chem. 2014;66:25-77.
Leung F, et al. Adv Clin Chem. 2014;66:25-77.
BRCA Testing in Action: Personal Stories - December 30, 2014
Feature: Peering into my genome, by Jennifer Couzin-Frankel, Science Magazine, Dec 4
by Jennifer Couzin-Frankel, Science Magazine, Dec 4CDC blog post: Knowing BRCA changed my life, Debbie Wasserman Schultz (June, 2014)
The REAL story of Mary-Claire King, by andrea, Brave Bosom Blog Post, Nov 20
by andrea, Brave Bosom Blog Post, Nov 20Public Health Genomics in Action: Hereditary Breast and Ovarian Cancer - December 4, 2014
Hereditary breast and ovarian cancer in public health, Genetic Alliance, webinar, Nov 21
Genetic Alliance, webinar, Nov 21Recent insights
Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: A randomized controlled trial.
Ranjit Manchanda, et al. JNCI, January, 2015
Ranjit Manchanda, et al. JNCI, January, 2015
'Screen more' for cancer risk genes, by James Gallagher, BBC, Nov 30
by James Gallagher, BBC, Nov 30Celebrities: Genetics and Breast Cancer - November 6, 2014
'Angelina Jolie effect': BRCA testing doubles, by Zosia Chustecka, Medscape, Sept 3
by Zosia Chustecka, Medscape, Sept 3Cancer information seeking in the digital age: Effects of Angelina Jolie's prophylactic mastectomy announcement
Noar SM, et al. Med Decis Making 2014 Oct
Noar SM, et al. Med Decis Making 2014 Oct
Celebrity disclosures and information seeking: the case of Angelina Jolie
Juthe RH, et al. Genet Med 2014 Oct
Juthe RH, et al. Genet Med 2014 Oct
The Angelina effect: immediate reach, grasp, and impact of going public.
Borzekowski DL et al. Genet Med. 2014 Jul;16(7):516-21.
Borzekowski DL et al. Genet Med. 2014 Jul;16(7):516-21.
Angelina Jolie's faulty gene: newspaper coverage of a celebrity's preventive bilateral mastectomy in Canada, the United States, and the United Kingdom.
Kamenova K et al. Genet Med. 2014 Jul;16(7):522-8.
Kamenova K et al. Genet Med. 2014 Jul;16(7):522-8.
Breast Cancer: Genomics in Prediction and Stratified Screening - October 30, 2014
The role of genome sequencing in personalized breast cancer prevention.
Weiva Sieh, et al. Cancer Epidemiology Biomarkers and Prevention, October 23, 2014
Weiva Sieh, et al. Cancer Epidemiology Biomarkers and Prevention, October 23, 2014
Cancer genomics: Using big data to advance breast cancer risk prediction, by Srivani Ravoori, AACR blog post, Oct 23
by Srivani Ravoori, AACR blog post, Oct 23Breast and Ovarian Cancer Genetics: Clinical and Public Health Approaches - October 16, 2014
New CDC podcast: CDC Medscape Expert Commentary:Genetics and BRCA in Primary Care. Katherine Kolor, October 13, 2014
Katherine Kolor, October 13, 2014
[PDF 428.18 KB]CDC information: Does breast or ovarian cancer run in your family?
CDC BRCA assessment tool for women: The Know:BRCA Assessment can help you assess your risk of having a BRCA mutation. Learning your risk can help you and your doctor make important decisions for your health
CDC BRCA assessment tool for clinicians: Help women Know:BRCA
Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: Recommendations from the U.S. Preventive Services Task Force
Ann Intern Med. 2014;160(4):I-16. doi:10.7326/P14-9008
Ann Intern Med. 2014;160(4):I-16. doi:10.7326/P14-9008
CDC Public health genomics implementation tool kit for health departments- check out BRCA section
No hay comentarios:
Publicar un comentario